Europe's labs had a good week. Its balance sheets had a harder one.
A Delft group found a way around the wiring problem that has kept silicon quantum chips small. A Scottish biotech raised enough to reach the clinic, and a French launch subsidiary found out it was worth keeping alive.
Underneath all of it, the same question keeps surfacing: who ends up owning the thing once it works.
Lead
A Single Electron Rewires the Silicon Quantum Chip
Researchers at QuTech, the quantum institute at Delft University of Technology, published a five-qubit silicon processor in Nature on August 4 in which one mobile electron spin shuttles between four stationary qubits. Instead of fixed wiring between every pair, the moving electron carries the interaction to wherever it is needed.
The mobile qubit travelled 1.2 micrometres in total and completed a weight-four parity check, the operation quantum error correction is built on.
Wiring congestion and crosstalk are the reasons spin qubits have stayed small. Silicon spin qubits are also the only qubit type that a conventional chip fab could make at volume, which is why a result about connectivity, not qubit count, is the one worth reading twice.
Biotech & Life Sciences
Mironid Raises $46 Million to Get a Kidney Drug Into the Clinic
Mironid, a Glasgow biopharmaceutical company spun out of the University of Strathclyde, closed a $46 million Series B on August 5. The Scottish National Investment Bank led as a new investor, alongside existing backers Roche Venture Fund, Sofinnova Partners, Epidarex Capital and BioGeneration Ventures.
The drug activates long-form PDE4 enzymes to break down cyclic AMP, the signal that drives cyst growth in autosomal dominant polycystic kidney disease. Around 12.4 million people have the condition, and the only approved targeted treatment, Otsuka's tolvaptan, carries a risk of severe liver damage.
This is Mironid's first round since an extended Series A in 2023, and the CEO says it funds the company through to initial clinical data. A national investment bank taking the lead on a first-in-class mechanism is the kind of position European public capital usually leaves to someone else.
Actimed Takes Back the Drug It Licensed Out Five Years Ago
Actimed Therapeutics announced on August 6 that it has reacquired global rights to S-oxprenolol from Faraday Pharmaceuticals. The Ascot company had licensed the compound to Faraday in 2021 for cancer cachexia and every indication except ALS.
Actimed now holds development, manufacturing and commercialisation rights worldwide. Cachexia, the muscle wasting that kills a large share of late-stage cancer patients, still has no approved treatment.
The standard European pattern is to license an asset to a US partner and wait. Pulling one back is a bet that the company can run the programme itself, which is the harder and more useful thing to find out.
Quantum & Photonics
Zeiss Backs a Finnish Eye Sensor Built to Run on Almost Nothing
SeeTrue Technologies, based in Joensuu in eastern Finland, raised €2.2 million on August 6 to commercialise an ultra-low-power eye-sensing architecture. ZEISS Ventures led, with Superhero Capital, the North Karelia Growth Fund managed by Redstone Nordics, and the company's founding angels.
Eye tracking is the power budget problem in smart glasses: the sensing works, it just drains the battery. SeeTrue's pitch is to shrink it far enough that the tracking becomes invisible to the wearer.
A German optics group funding a North Karelian sensor startup is a reminder that Europe's photonics supply chain runs through places with no tech-hub branding at all.
Space
A Think Tank Says Europe Is Losing the Orbital Data Centre Race
The European Space Policy Institute published a report on August 5 warning that Europe risks handing orbital compute to the United States and China. China's Three-Body Constellation has been operational since 2025, with further ventures planning networks of 2,800 and more than 1,000 satellites.
Two American orbital data centre startups are now valued above $1 billion. Europe is still running research projects and small demonstrations without a coordinated strategy.
ESPI's recommendations are specific rather than despairing: a flagship EU initiative inside the 2028 to 2034 research programme, ESA and the Commission acting as early customers to signal demand, and a European orbital data centre challenge for startups. Whether any of it lands depends on the next budget cycle, which is where Europe's space ambitions usually get trimmed.
ArianeGroup Decides Not to Shut MaiaSpace
MaiaSpace posted a €37.5 million loss for 2025 and ended the year with shareholders' equity below zero, according to annual accounts filed on 22 July and reported on August 3. Under French company law, that forced ArianeGroup to formally decide whether to dissolve its reusable launcher subsidiary.
It decided against. The company still holds €114.2 million in cash, so the decision was about mandate rather than solvency.
Europe has one credible small reusable launcher programme inside its incumbent launch group, and it just had to be actively rescued from its own accounts. That is worth remembering the next time the continent's launch strategy is described as settled.
Europe's Forests Are Losing 46% More Biomass Per Disturbed Hectare
ESA published findings on August 5, produced with the Technical University of Munich and France's Laboratory of Climate and Environmental Sciences, showing that since 2018 each hectare of disturbed European forest loses 46% more biomass than before. Between 1985 and 2023, disturbances removed 6.5 billion tonnes of above-ground biomass.
Logging accounts for about 82% of the loss and natural disturbance for the rest. The post-2018 droughts across Germany, the Czech Republic and Poland weakened trees enough for spruce bark beetle outbreaks to do the remainder.
Europe's forests hold 10.6 billion tonnes of carbon, and the projected sink is down 39% between 2010 and 2030. The work came out of ESA's Climate Change Initiative using the Landsat archive, which means the measurement infrastructure for checking climate accounts against reality now exists whether or not the accounts get revised.
(ESA)
Robotics & Automation
Monava's Passive Drone Sensors Are Selling Faster Than It Expected
Monava, a Swedish-Finnish company split between Stockholm and Helsinki, closed a round of about €500,000 on August 4, led by Gungnir Capital with Foundry Ventures and Hede Capital. Its sensors use AI-driven acoustic sensing to detect, track and classify drones without emitting anything a counterparty could locate.
The systems are deployed across the Nordics and in Ukraine, developed through testing with armed forces. Its chief executive says the number of enquiries now runs well past what the company planned for.
Radar announces itself. In contested airspace, where emitting is what gets you found, listening turns out to be the product.
(Tech.eu)
Semiconductors
NXP Looks at a $3 Billion Purchase in California
NXP is in exploratory talks to acquire Ambarella, the California designer of AI image-processing chips for driver assistance and autonomous driving, in a deal reported on August 3 at more than $3 billion. No agreement has been reached and neither company has commented.
NXP chief executive Rafael Sotomayor has tied the company's recent results to AI moving out of the cloud and into vehicles, factories and robots. Buying Ambarella would buy the edge inference silicon rather than build it.
Europe's largest automotive chip maker closing its physical-AI gap through a US acquisition is a familiar shape. It works, and it also moves the design capability further from the continent that keeps writing strategies about retaining it.
One to Watch
Pasqal's Shareholders Vote on August 25
The SEC declared Pasqal's Form F-4 effective on August 5, clearing the way for its combination with Bleichroeder Acquisition Corp. II. Bleichroeder shareholders vote on August 25.
We flagged the $2 billion pre-money listing when it was announced in June, and Pasqal's move to make its neutral-atom processors schedulable inside HPC clusters in July. The Nasdaq listing under the ticker PSQL is expected in the second half of this year, targeting around $500 million in proceeds.
Watch the redemption rate at that vote. It is the number that decides whether France's largest quantum company arrives on Nasdaq funded or merely listed.